A Phase II Study of PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and
safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects
with inoperable HCC.